Definium Therapeutics, Inc. (DFTX) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price

Definium Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price

Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $9.42 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06

• Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was 1.33 CAD/shares.
• Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was 17.29 CAD/shares, a 37.98% decline from fiscal 2022.
• Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was 27.88 CAD/shares, a 1642.50% increase from fiscal 2021.
• Definium Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was 1.60 CAD/shares.